These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32430573)

  • 21. Postural tremor and chronic inflammatory demyelinating polyneuropathy.
    Cao Y; Menon P; Ching-Fen Chang F; Mahant N; Geevasinga N; Fung VS; Vucic S
    Muscle Nerve; 2017 Mar; 55(3):338-343. PubMed ID: 27421831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy.
    Lawley A; Abbas A; Seri S; Rajabally YA
    Muscle Nerve; 2020 Aug; 62(2):226-232. PubMed ID: 32388856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective analysis of gait characteristics in chronic inflammatory demyelinating polyradiculoneuropathy.
    Bozovic I; Peric S; Basta I; Rakocevic-Stojanovic V; Lavrnic D; Stevic Z; Radovanovic S
    J Clin Neurosci; 2020 Oct; 80():6-10. PubMed ID: 33099368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Ricciardi D; Tedeschi G
    Muscle Nerve; 2019 Dec; 60(6):662-667. PubMed ID: 31415091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance.
    Merkies IS; van Nes SI; Hanna K; Hughes RA; Deng C
    J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1194-9. PubMed ID: 20647554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of social-functioning and sleep on quality of life in chronic inflammatory demyelinating polyneuropathy.
    Englezou C; Nazeer KK; Rajabally YA
    Clin Neurol Neurosurg; 2023 Nov; 234():108017. PubMed ID: 37866209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early predictive factors of disability in CIDP.
    Spina E; Topa A; Iodice R; Tozza S; Ruggiero L; Dubbioso R; Esposito M; Bruzzese D; Santoro L; Manganelli F
    J Neurol; 2017 Sep; 264(9):1939-1944. PubMed ID: 28770373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and determinants of pain in chronic inflammatory demyelinating polyneuropathy: Results from the German INHIBIT registry.
    Mork H; Motte J; Fisse AL; Grüter T; Brünger J; Stoykova Z; Bulut Y; Athanasopoulos D; Sturm D; Tegenthoff M; Gold R; Enax-Krumova E; Pitarokoili K
    Eur J Neurol; 2022 Jul; 29(7):2109-2120. PubMed ID: 35357725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study.
    Liu B; Hu J; Sun C; Qiao K; Xi J; Zheng Y; Sun J; Luo S; Zhao Y; Lu J; Lin J; Zhao C
    J Neurol; 2023 Sep; 270(9):4288-4295. PubMed ID: 37195346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy.
    Klehmet J; Beutner S; Hoffmann S; Dornauer M; Paul F; Reilmann R; Brandt AU; Meisel A
    BMC Neurol; 2019 Jun; 19(1):118. PubMed ID: 31176377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies.
    Reynolds J; Sachs G; Stavros K
    R I Med J (2013); 2016 Dec; 99(12):32-35. PubMed ID: 27902997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of the COVID-19 pandemic on patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Stojanov A; Bozovic I; Stojanov J; Palibrk A; Djordjevic G; Basta I; Malobabic M; Arsic AA; Peric S
    Clin Neurol Neurosurg; 2021 Apr; 205():106654. PubMed ID: 33932773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of psychiatric distress and physical disability on quality of life in neuromyelitis optica spectrum disorder and chronic autoimmune demyelinating polyneuropathies.
    Yalachkov Y; Soydaş D; Uhlmann V; Behrens M; Frisch S; Foerch C; Gehrig J
    Mult Scler Relat Disord; 2021 Feb; 48():102711. PubMed ID: 33383364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
    Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
    Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database.
    Doneddu PE; Cocito D; Manganelli F; Fazio R; Briani C; Filosto M; Benedetti L; Mazzeo A; Marfia GA; Cortese A; Fierro B; Jann S; Beghi E; Clerici AM; Carpo M; Schenone A; Luigetti M; Lauria G; Antonini G; Rosso T; Siciliano G; Cavaletti G; Liberatore G; Santoro L; Peci E; Tronci S; Ruiz M; Cotti Piccinelli S; Toscano A; Mataluni G; Piccolo L; Cosentino G; Sabatelli M; Nobile-Orazio E;
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):125-132. PubMed ID: 30297520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyneuropathies and chronic inflammatory demyelinating polyradiculoneuropathy in multiple sclerosis.
    Suanprasert N; Taylor BV; Klein CJ; Roforth MM; Karam C; Keegan BM; Dyck PJB
    Mult Scler Relat Disord; 2019 May; 30():284-290. PubMed ID: 30870805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Muscle performance relates to physical function and quality of life in long-term chronic inflammatory demyelinating polyradiculoneuropathy.
    Harbo T; Andersen H; Overgaard K; Jakobsen J
    J Peripher Nerv Syst; 2008 Sep; 13(3):208-17. PubMed ID: 18844787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy.
    Grüter T; Motte J; Fisse AL; Bulut Y; Köse N; Athanasopoulos D; Otto S; Yoon MS; Schneider-Gold C; Gold R; Pitarokoili K
    Eur J Neurol; 2020 Dec; 27(12):2595-2603. PubMed ID: 32794258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insights into the management of chronic inflammatory demyelinating polyradiculoneuropathy.
    Rajabally YA; Blomkwist-Markens PH; Katzberg HD
    Neurodegener Dis Manag; 2015; 5(3):257-68. PubMed ID: 26107324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.